scholarly journals In vitro effects of dipyridamole and aspirin on whole blood platelet aggregation and ATP release.

Nosotchu ◽  
2000 ◽  
Vol 22 (2) ◽  
pp. 343-347
Author(s):  
Tomomi Nakamura ◽  
Shinichiro Uchiyama ◽  
Masako Yamazaki ◽  
Makoto Iwata
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Atp Release ◽  
Blood Platelet ◽  
In Vitro Effects ◽  
Blood Platelet Aggregation

scholarly journals Erythropoietin does not increase whole-blood platelet aggregation in vitro

1994 ◽  
Vol 9 (5) ◽  
pp. 556-558
Author(s):  
J. E. Taylor ◽  
J. J. F. Belch ◽  
I. S. Henderson ◽  
W. K. Stewart
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Blood Platelet ◽  
Blood Platelet Aggregation

MEASURING WHOLE BLOOD PLATELET AGGREGATION AND ATP-RELEASE WITH A CHRONO-LOG WHOLE BLOOD LUMI-AGGREGOMETER: EFFECT OF STORAGE TIME OF BLOOD SAMPLES

1987 ◽  
Author(s):  
F C Sieders ◽  
A C v Houwelingen ◽  
G Hornstra
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Storage Time ◽  
Bleeding Time ◽  
Atp Release ◽  
Blood Platelet ◽  
Blood Samples ◽  
Before And After ◽  
Positive Correlations ◽  
Blood Platelet Aggregation

The influence of storing blood for either one or two hours after blood sampling, on whole blood platelet aggregation and ATP-release was measured with a Chrono-log whole blood lumi-aggregometer, in 21 healthy male volunteers. Storage of blood samples, gently revolving at 37 °C in an incubator for one hour, caused a significant increase in aggregation and release as compared with results obtained immediately after sampling. After two hours' storage, the values had returned to their initial levels.Significant positive correlations were seen between values obtained before and after storage of blood, and between various aggregation and release parameters. In this study, bleeding time nor hematocrit values were significantly correlated with the aggregation and release parameters. The considerable influence of storage time on whole blood platelet aggregation and ATP-release underlines the importance of performing these determinations immediately after sampling, or possibly after a standardized storage time. Otherwise, comparison of results -obtained either in clinical situations or in trials - will increase variability as a result of which false conclusions may be obtained. This will be illustrated in a small trial using paracetamol.

scholarly journals Whole-Blood Platelet Aggregation Predicts In Vitro and In Vivo Primary Hemostatic Function in the Elderly

1995 ◽  
Vol 15 (6) ◽  
pp. 748-753 ◽  
Author(s):  
Jonathan D. Emery ◽  
David W. Leifer ◽  
Glaci L. Moura ◽  
Patricia Southern ◽  
James H. Morrissey ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Blood Platelet ◽  
The Elderly ◽  
Blood Platelet Aggregation

Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro

1986 ◽  
Vol 41 (4) ◽  
pp. 509-518 ◽  
Author(s):  
IA Greer ◽  
JJ Walker ◽  
M McLaren ◽  
AA Calder ◽  
CD Forbes
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Blood Platelet ◽  
Blood Platelet Aggregation

scholarly journals Whole Blood Platelet Aggregation and Release Reaction Testing in Uremic Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Jay Zeck ◽  
Jason Schallheim ◽  
Susie Q. Lew ◽  
Louis DePalma
Keyword(s):  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Whole Blood ◽  
Low Dose ◽  
Reference Range ◽  
Atp Release ◽  
Blood Platelet ◽  
Ckd Stage ◽  
Uremic Patients ◽  
Blood Platelet Aggregation

Background. Platelet function analysis utilizing platelet-rich plasma and optical density based aggregometry fails to identify patients at risk for uremia associated complications.Methods. We employed whole blood platelet aggregation analysis based on impedance as well as determination of ATP release from platelet granules detected by a chemiluminescence method. Ten chronic kidney disease (CKD) stage 4 or 5 predialysis patients underwent platelet evaluation. Our study aims to evaluate this platform in this patient population to determine if abnormalities could be detected.Results. Analysis revealed normal aggregation and ATP release to collagen, ADP, and high-dose ristocetin. ATP release had a low response to arachidonic acid (0.37 ± 0.26 nmoles, reference range: 0.6–1.4 nmoles). Platelet aggregation to low-dose ristocetin revealed an exaggerated response (20.9 ± 18.7 ohms, reference range: 0–5 ohms).Conclusions. Whole blood platelet analysis detected platelet dysfunction which may be associated with bleeding and thrombotic risks in uremia. Diminished ATP release to arachidonic acid (an aspirin-like defect) in uremic patients may result in platelet associated bleeding. An increased aggregation response to low-dose ristocetin (a type IIb von Willebrand disease-like defect) is associated with thrombus formation. This platelet hyperreactivity may be associated with a thrombotic diathesis as seen in some uremic patients.

Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro

1995 ◽  
Vol 78 (2) ◽  
pp. 161-171 ◽  
Author(s):  
Ralf Knöfler ◽  
Takamitsu Nakano ◽  
Katsuyuki Nakajima ◽  
Yumiko Takada ◽  
Akikazu Takada
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Blood Platelet ◽  
Blood Platelet Aggregation

Effects of Acetylsalicylic Acid on Inhibition of Ex Vivo Platelet Aggregation and Secretion by SKF 107260, a Novel GPIIb/IIIa Receptor Antagonist

1994 ◽  
Vol 72 (04) ◽  
pp. 622-626 ◽  
Author(s):  
Martin I Freed ◽  
Steven Boike ◽  
Nevine Zariffa ◽  
Diane K Jorkasky
Keyword(s):  
Platelet Aggregation ◽  
Acetylsalicylic Acid ◽  
Whole Blood ◽  
Ex Vivo ◽  
Atp Release ◽  
Blood Platelet ◽  
Inhibition Of Platelet Aggregation ◽  
Dependent Inhibition ◽  
Platelet Secretion

SummarySKF 107260 is a potent pentapeptide antagonist of the platelet membrane glycoprotein receptor GP IIb/IIIa. The in vitro platelet inhibitory effects of SKF 107260, acetylsalicylic acid (ASA), and their combination, on collagen-induced platelet aggregation and secretion (ATP release) were assessed in human whole blood. Additionally, the con-centration-response relationships for these inhibitors were compared for males and females in order to explore gender differences in platelet responsiveness. SKF 107260 caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations ≥30 nM. ASA also caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations ≥ 1 mg/dl. The addition of ASA 1 mg/dl to increasing concentrations of SKF 107260 resulted in a more pronounced inhibition of platelet aggregation than when either agent was used alone. These data suggest a pharmacologic interaction, especially at SKF 107260 concentrations ≤30 nM. Since ATP release was significantly inhibited at concentrations ≥ 1 nM, platelet secretion appears to be more sensitive than aggregation to inhibition by SKF 107260. These data suggest that platelet secretion in response to collagen is dependent on the aggregation response mediated by GP IIb/IIIa. In conclusion, SKF 107260 is a potent inhibitor of both whole blood platelet aggregation and secretion and these anti-aggregatory effects may be augmented by concomitant ASA administration.

Sign in / Sign up

Export Citation Format

Share Document